Scynexis (SCYX) Gains from Investment Securities (2013 - 2026)
Scynexis' (SCYX) quarterly Gains from Investment Securities came in at $5.2 million in Q1 2026, up 279.27% YoY from $1.4 million in Q1 2025, and up 512.33% on a QoQ basis from -$1.3 million in Q4 2025.
Scynexis (SCYX) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 13 years of Gains from Investment Securities data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 279.27% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 134.12% YoY) and the FY2025 annual result came in at -$5.8 million, up 58.2% from the prior year.
- Gains from Investment Securities improved to $5.2 million in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $21.7 million in Q3 2022 to a low of -$10.0 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of -$2.9 million in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities sank 673.92% — and 2023, when it jumped 316.08%.
- Tracing SCYX's Gains from Investment Securities over 5 years: stood at -$9.1 million in 2022, then jumped by 69.18% to -$2.8 million in 2023, then slipped by 14.79% to -$3.2 million in 2024, then surged by 60.39% to -$1.3 million in 2025, then surged by 512.33% to $5.2 million in 2026.
- The last three Gains from Investment Securities figures came in at $5.2 million (Q1 2026), -$1.3 million (Q4 2025), and $640000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Scynexis | 61.90 Mn | -52.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.15 Mn |
| Jun 30, 2026 | -14.15 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -1.27 Mn |
| Dec 31, 2025 | -1.27 Mn |
| Sep 30, 2025 | 640,000.00 |
| Sep 30, 2025 | 640,000.00 |
| Jun 30, 2025 | -2.17 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Mar 31, 2025 | -2.93 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Sep 30, 2024 | -6.80 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |